Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.

Published

Journal Article

In the ION-4 trial, hepatitis C virus relapse was rare, occurring only in African American patients, 80% receiving efavirenz for human immunodeficiency virus infection. We observed no indication that CYP2B6 polymorphisms associated with increased plasma efavirenz exposure explained the relapses.

Full Text

Duke Authors

Cited Authors

  • Kleinstein, SE; Shea, PR; Stamm, LM; Sulkowski, M; Goldstein, DB; Naggie, S

Published Date

  • March 7, 2018

Published In

PubMed ID

  • 29522085

Pubmed Central ID

  • 29522085

Electronic International Standard Serial Number (EISSN)

  • 1537-6591

International Standard Serial Number (ISSN)

  • 1058-4838

Digital Object Identifier (DOI)

  • 10.1093/cid/cix1051

Language

  • eng